AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05170737
Drug: AEF0217
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort.~PART III: A total of 12 healthy male subjects will be randomly assigned to one of two sequences in the crossover study part. All subjects will receive the same dose of AEF0117 which will be determined following the results of the FIH-SAD.
Trial: NCT05170737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort.
Trial: NCT05383677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
Trial: NCT06572917
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 0.1 mg/kg dose intravenous indomethacin as a slow infusion over 20 mins
Trial: NCT06572917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of intravenous normal saline placebo as a slow infusion over 20 mins
Trial: NCT05509257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of medication in randomized, crossover fashion with a 2 week wash out period between interventions.. Medication will be taken 2 hours prior the neuroimaging.
Trial: NCT06562816
Drug: Naproxen Sodium 550mg
RxNorm normalized name: Naproxen Sodium 550mg Oral tablet
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 550mg
Trial: NCT05058872
Drug: Levonorgestrel/ethinyl estradiol
RxNorm normalized name: levonorgestrel/ethinyl estradiol 0.1 mg-20 mcg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 0.15mg/ethinyl estradiol 0.03mg
Trial: NCT05058872
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT05595473
Drug: RZ-001 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RZ-001 Dose 1 and VGCV
Trial: NCT05595473
Drug: RZ-001 Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RZ-001 Dose 2 and VGCV
Trial: NCT05595473
Drug: RZ-001 Dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RZ-001 Dose 3 and VGCV
Trial: NCT05595473
Drug: RZ-001 Dose 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RZ-001 Dose 4 and VGCV
Trial: NCT05327530
Drug: NKTR-255
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive NKTR-255 intravenous infusion at a dose of 3 micrograms per kilogram body weight (mcg/kg) once every 4 weeks (Q4W) in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Trial: NCT06104683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00850512
Drug: CHOP21-R
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four months for CHOP21-R and two treatment days one week apart
Trial: NCT05372315
Drug: Dextenza 0.4Mg Ophthalmic Insert
RxNorm normalized name: Dextenza 0.4mg Ophthalmic Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (dexamethasone ophthalmic insert)-for the treatment of ocular inflammation and pain following following ophthalmic surgery.
Trial: NCT05427630
Drug: THC ~2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis flower containing THC \~2.5%
Trial: NCT05427630
Drug: THC ~5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis flower containing THC \~5%
Trial: NCT05427630
Drug: THC ~10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis flower containing THC \~5%
Trial: NCT05465681
Drug: HR20013 for injection；dexamethason
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy.~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy
Trial: NCT06178640
Drug: Simvastatin 40 mg film-coated tablet
RxNorm normalized name: simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg film-coated tablet
Trial: NCT06178640
Drug: Zocor 40 mg film-coated tablet
RxNorm normalized name: simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zocor 40 mg film-coated tablet (Simvastatin 40 mg film-coated tablet: Reference Product)
Trial: NCT05045053
Drug: Xiidra 5% Ophthalmic Solution
RxNorm normalized name: Xiidra 5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lifitegrast 0.5% ia applied twice daily after corneal collagen cross linking
Trial: NCT05459805
Drug: traditional chinese medicine Xuanfei-Zhike formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200ml, bid, for 8 weeks
Trial: NCT06342167
Drug: Programmed Cell Death Protein 1 Inhibitor
RxNorm normalized name: Programmed cell death protein 1 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of Sintilimab administered every three weeks concurrently with radiotherapy and after radiotherapy as consolidation therapy up to 1year.
Trial: NCT01539265
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05578521
Drug: Cerebralcare pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a dose of 2 packages, twice a day of Cerebralcare pills
Trial: NCT05578521
Drug: Cerebralcare pills placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebralcare pills placebo will be administrated at the same rate with experimental group
Trial: NCT06512402
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive norepinephrine infusion at rate of 0.05 mcg/Kg/min
Trial: NCT06512402
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive epinephrine infusion dose of 0.03 mcg/Kg/min
Trial: NCT04309721
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of placebo of Perampanel, administered orally. Placebo of perampanel will be given orally, in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, Placebo of perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
Trial: NCT05165394
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration
Trial: NCT06111326
Drug: BC3402 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion, once every 2 weeks, 4 weeks/cycle.
Trial: NCT05509244
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen 1g iv dripping at end of surgery
Trial: NCT05509244
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen 300mg iv dripping at end of surgery
Trial: NCT06289725
Drug: antiviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient was treated with antiviral drugs according to the protocol of the Ministry of Health of Vietnam 2019
Trial: NCT05012566
Drug: Vistabex
RxNorm normalized name: ascorbic acid / biotin / calcium pantothenate / folic acid / niacinamide / pyridoxine hydrochloride / riboflavin / thiamine mononitrate Oral Tablet [Vitabee with C]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vistabex: 50U/vial, it is injected up to 80U per patient per treatment (2 treatment sessions at a 4 months interval)
Trial: NCT06037655
Drug: Total Neoadjuvant Treatment
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab (1200 mg) every three weeks intravenously; Mecapegfilgrastim (6 mg) every three weeks intravenously; Gemcitabine (1000 mg/m2) every three weeks on days 1 and 8 intravenously; Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously
Trial: NCT04936880
Drug: Control: Analgesia-sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
Trial: NCT05111249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo oral solution once weekly
Trial: NCT05964738
Drug: Diuretics withdrawal
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics that not have been demonstrated improve survival in chronic HFrEF are withdrawn
Trial: NCT05964738
Drug: Diuretics maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any diuretic could be used
Trial: NCT05635838
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Trial: NCT05955027
Drug: ZX-7101A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a drug to treat influenza, oral
Trial: NCT05955027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo control, oral
Trial: NCT06530849
Drug: GC012F Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC012F Injection is an autologous chimeric antigen receptor T cell therapy targeting both BCMA and CD19
Trial: NCT05153408
Drug: BLU-701
RxNorm normalized name: Blu-Kote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLU-701 for oral administration
Trial: NCT04918589
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL topical of 0.9% normal saline
Trial: NCT06052462
Drug: [14C]-LY3556050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04887311
Drug: MBM-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered study drug daily for 9 months QD via premarked medicine cups.
Trial: NCT02082691
Drug: G-202
RxNorm normalized name: krill/om-3/dha/epa/phospho/ast 500 mg-86 mg-25 mg-40 mg-202 mg-101 mcg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will receive G-202 for 3 days in a row, followed by 25 days without taking G-202. This cycle will be repeated every 28 days. Patient will receive G-202 as long as his/her cancer does not grow and the investigational drug side effects are tolerable.
Trial: NCT06086912
Drug: HR17031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive a single dose of HR17031 at every period (First period：abdomen. Second period. upper arm. Third period: thigh).
Trial: NCT06086912
Drug: HR17031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive a single dose of HR17031 at every period (First period：upper arm. Second period: thigh. Third period: abdomen).
Trial: NCT06086912
Drug: HR17031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive a single dose of HR17031 at every period (First period：thigh. Second period: abdomen. Third period: upper arm).
Trial: NCT05880914
Drug: Standard treatment for bone disorder
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be prescribed a clinically indicated bone-targeted treatment for osteoporosis or bone disorder related to CKD. (non-experimental)
Trial: NCT05689827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was used in the same way
Trial: NCT05748600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of placebo tablet
Trial: NCT05418361
Drug: ACE inhibitor ,angiotensin receptor blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients taking ACEI or ARBs with cardiovascular disease
Trial: NCT04853797
Drug: Levcromakalim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 min infusion of 1 mg Levcromakalim followed by either oral Ivabradine or Placebo.
Trial: NCT04853797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (calcium supplements).
Trial: NCT05669885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will be allocated to receive oral administration of placebo.
Trial: NCT06202261
Drug: TQB2930 for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2930 for injection is a HER2 bispecific antibody.
Trial: NCT06202261
Drug: TQB3616 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3616 capsule is a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
Trial: NCT06202261
Drug: Capecitabine tablets
RxNorm normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is converted to 5-fluorouracil (5-FU) by in vivo enzyme action.
Trial: NCT05420012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A starting dose of vericiguat 2.5 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Subjects will be up-titrated in a blinded fashion to 5 mg and then to the target dose of 10 mg of vericiguat or matching placebo using titration criteria based on mean systolic blood pressure(SBP) evaluation and clinical symptoms at 2 week intervals. Titration to 10 mg in subjects who have not yet reached the target dose is intended at every visit/phone call throughout the study duration based on mean SBP measurement and safety considerations, at the discretion of the investigator.
Trial: NCT05396118
Drug: Injection of hyperpolarized [1-13C]Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of one bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by magnetic resonance spectroscopy (MRS) / magnetic resonance spectroscopy imaging (MRSI). After a 5-30 min pause, injection of a second bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by MRS / MRSI.
Trial: NCT05211050
Drug: Levcromakalim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 min infusion of 1 mg Levcromakalim followed by either sumatriptan or placebo.
Trial: NCT04679389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally or enterally
Trial: NCT06147037
Drug: FPI-2053
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPI-2053 is a bispecific antibody that targets EGFR and cMET
Trial: NCT06147037
Drug: [111In]-FPI-2107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[111In\]-FPI-2107 is an imaging agent in which indium-111 is conjugated to FPI-2053.~Participants will have a fixed dose of \[111In\]-FPI-2107 followed by imaging scans (with or without pre-administration of FPI-2053).
Trial: NCT06147037
Drug: [225Ac]-FPI-2068
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[225Ac\]-FPI-2068 is a radiopharmaceutical therapy in which an alpha emitter, actinium-225, is conjugated to FPI-2053.~Participants will be dosed through IV administration every 56 days for up to 3 cycles of the Treatment Period.
Trial: NCT05148494
Drug: Fleet Enema
RxNorm normalized name: Fleet Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard pre-op application, see arm description
Trial: NCT04776369
Drug: IV saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline IV 50 ml
Trial: NCT05652660
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Probe substrate
Trial: NCT05008510
Drug: Sabizabulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sabizabulin (Veru-111)
Trial: NCT05295329
Drug: Compound Danshen Dropping Pills
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use Compound Danshen Dropping Pills
Trial: NCT06434740
Drug: Puterizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Within 7-14 days after SBRT, Puterizumab should be used (dosage: recommended dosage of 200mg, intravenous infusion, infusion time of 60 minutes (± 15 minutes), once every 3 weeks (Q3W), for 6-8 months or intolerable toxicity).
Trial: NCT05491642
Drug: BAY3283142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT05491642
Drug: Placebo to BAY3283142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT05113004
Drug: Mycophenolate mofetil 2000mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
Trial: NCT05113004
Drug: Placebo of Mycophenolate mofetil 2000mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
Trial: NCT06017284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 100 mg/day, once a day, orally intake at night.
Trial: NCT04804553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive the matching placebo orally.
Trial: NCT04824872
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for dasiglucagon
Trial: NCT04634162
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be infused for 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
Trial: NCT05176210
Drug: PS1
RxNorm normalized name: ACL11SPS12 NERVE BLOCK KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.
Trial: NCT05176210
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be provided as a 120 mg tablet.
Trial: NCT05677945
Drug: 3Mixtatin paste: Simvastatin mixed with modified triple antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Drying the mucosa with gauze,topical anesthesia will be applied.~* Administration of local anesthesia with vasoconstrictor.~* Rubber dam isolation.~* Caries removal \& access cavity using a round bur mounted on a high-speed contra with coolant.~* Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~* Radicular section will be kept untouched,no instrumentation.~* Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~* In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~* Drying the access cavity with sterile cotton pellets.~* Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier \& condensed over orifices using a moist cotton pellet.~* Cavity sealing with RMGI capsules.~* Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement.
Trial: NCT05677945
Drug: 3Mix: Modified triple antibiotic mix in propylene glycol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Drying the mucosa with gauze,topical anesthesia will be applied.~* Administration of local anesthesia with vasoconstrictor.~* Rubber dam isolation.~* Caries removal \& access cavity using a round bur mounted on a high-speed contra with coolant.~* Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~* Radicular section will be kept untouched,no instrumentation.~* Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~* In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~* Drying the access cavity with sterile cotton pellets.~* Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier \& condensed over orifices using a moist cotton pellet.~* Cavity sealing with RMGI capsules.~* Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement.
Trial: NCT05282706
Drug: Mandarin Oil
RxNorm normalized name: mandarin oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A hydrogel mandarin oil infused aromatherapy patch
Trial: NCT06489626
Drug: Methylprednisolone 4 milligram Tab
RxNorm normalized name: methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-day 4 milligram methylprednisolone oral taper
Trial: NCT04267237
Drug: RO7198457
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7198457 will be administered by IV infusion at protocol-defined intervals for 12 cycles.